Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case report

Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case report

BackgroundFibroblast growth factor receptor-2 (FGFR-2) mutations are frequently observed in intrahepatic cholangiocarcinoma (ICC). While FGFR2-targeted therapies are primarily studied in advanced ICC, this report presents a rare case of locally recurrent ICC treated with systemic therapy, leading to...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuchen Yang, Jingfeng Li, Di Ma, Fengjie Hao, Weixia Li, Jing Xie, Lihan Qian, Junqing Wang, Yongjun Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Oncology
Subjects:
intrahepatic cholangiocarcinoma
FGFR-2
systemic therapy
locally advanced recurrence
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1527372/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items